KININ2018CLE
KININ2018CLE
批准号:
9471651
负责人:
ALVIN H SCHMAIER
金额:
$1.25万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-01 至 2019-03-31
关键词:
AcademiaAcuteAddressAngiotensin IIAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsAngiotensinsAppointmentAreaAwardBasic ScienceBiochemistryBiologicalBiologyBlood coagulationBradykininBradykinin ReceptorCardiologyCardiovascular DiseasesClinicalCollaborationsCommunicationComplementComplement ActivationCongressesDevelopmentDiabetes MellitusDisciplineDiseaseDoctor of PhilosophyDrug IndustryEmbryonic DevelopmentEnzymesEvaluationFactor XIIFactor XIIaFertilizationFibrinolysisFosteringFundingFutureG-Protein-Coupled ReceptorsGenerationsGoalsGrantGrowthGrowth and Development functionHeart failureHematologyHemorrhageHigh-Molecular-Weight KininogenHypertensionImmunologyIncidenceIndividualIndustryIndustry CollaborationInflammationInternationalInvestigationKallikrein-Kinin SystemKininogenaseKininsKnowledgeLocationMeasuresMedical centerMinorityMissionMyocardial InfarctionNational Heart, Lung, and Blood InstituteNeprilysinOhioOralParticipantPathogenesisPeptidesPeptidyl-Dipeptidase APharmacologyPhysiologicalPlasmaPlasma KallikreinPostdoctoral FellowProteinsPublishingReninRenin-Angiotensin SystemRequest for ApplicationsResearchResearch PersonnelRiskRoleScienceScientistSenior ScientistSouth CarolinaStrokeStudentsSudden DeathSumSystemTherapeuticThrombosisTimeTrainingTranslatingTranslationsTravelUnited StatesUniversitiesUniversity HospitalsWomanWound Healingangiogenesisbasecareer developmentclinical developmentcofactordoctoral studentfrontierhereditary angioneurotic edemaimprovedinhibitor/antagonistinsightinstructorinterestknowledge translationmeetingsmembermouse modelmultidisciplinarynext generationnovelnovel therapeuticsposterspre-doctoralpreventprofessorreceptorstructural biologysuccesssymposiumteacher mentortherapeutic developmenttherapeutic targettherapy developmenttooltreatment strategy
中文摘要
项目摘要
要求支持一个独特的,国际性的,多学科的会议,题为KININ 2018 CLE
由Alvin H.放大图片作者:基思R.放大图片作者:Marvin Nieman,Sadashiva S. Karnik和
凯斯西储大学(CWRU)的杰克逊T赖特。 这次会议将在克利夫兰举行,
俄亥俄州的CWRU校园从2018年6月17日至2018年6月20日。 本次会议的主题是关于
NHLBI的使命,因为它庆祝知识的增长,在几个组成部分的等离子体接触,
激肽释放酶-血管紧张素和肾素血管紧张素系统以及将这些知识转化为治疗靶点
治疗多种心血管疾病 接触激活和血浆激肽释放酶-血管紧张素系统长期以来一直存在
已经认识到产生缓激肽并影响血液凝固、炎症、纤维蛋白溶解,
补体和肾素-血管紧张素系统。 这些系统由生物活性肽(例如,
缓激肽、血管紧张素II、血管紧张素1- 17),它们的G-β蛋白偶联受体(血管紧张素受体1和2,
缓激肽受体1和2,和Mas),产生这些生物肽的酶[因子XIIa,
血浆激肽释放酶、肾素、血管紧张素转换酶、羧肽酶原、中性内肽酶
(脑啡肽酶)]及其天然抑制剂C1抑制剂。 近年来,由药物治疗的疾病清单
针对这些系统的成员已经从高血压扩展到心脏衰竭,遗传性
血管性水肿和动脉血栓形成抑制而无出血风险。 这次会议是独一无二的,因为
它将汇集不同领域的思想领袖,以填补知识空白,交流思想,
建立新的协会,并在学术界和工业界建立新的合作。
本会议补助金(R13)申请要求为学员(预科博士生,
博士后研究生、讲师或助理教授)的会议注册、旅行和酒店。
这些国际基尼会议每三年在不同地点举行一次。 上一次是
2002年在美国南卡罗来纳州的查尔斯顿举行。 从那时起,新一代的
研究人员已经开发了由于几个发现:1)所有鼠模型的接触蛋白的影响
血栓形成的风险,而不出血; 102)多种新的目标已被用于减少缓激肽形成,
遗传性血管性水肿的管理; 103)因子XII以前未被认识的生物学机制
激活已经被认识到; 4)脑啡肽酶与血管紧张素受体1拮抗剂联合使用,
被认为是治疗心力衰竭的有效药物组合。 这些领域的研究势头
菲尔兹的杰出贡献推动了这次跨学科会议的召开。
KININ 2018 CLE的目标有几个方面:1)传播激肽的研究和临床进展
自上次在美国举行的会议以来,生物学; 102)汇集世界上最好的研究人员,
Kinins领域,用于分享研究和产生新的想法,以填补未来的知识空白
3)鼓励交叉学科研究,激发新的思想和独特的
研究机会; 104)强调激肽科学现在正在转化为临床的那些领域
使用; 5)培养该领域的下一代初级调查员,以实现他们的目标。
老师和导师都无法完成。
KININ 2018 CLE的目标有几个方面:1)促进沟通,分享想法,未来
参与者之间的合作; 102)澄清领域中的未知数,并将新知识与知识结合起来
对旧信息的解释; 103)在这些内容领域教育新一代调查人员; 104)
支持外地新调查员的职业发展; 105)促进学术界之间的合作
106)激发制药业对有潜力的新领域的兴趣,
治疗靶点的开发。KININ 2018 CLE的成功将通过几个评估来衡量
工具:1)我们将评估每位演讲者的客观性,质量,以及在演讲中缺乏商业偏见。
演讲; 102)会议结束时将进行全面的会议评估; 103)会议
将发表在《血液学前沿》上的报告; 104)每位演讲者的在线研讨会
报告将在会议结束后12个月内发表在《血液学前沿》上; 105)我们将
确定抽象演讲者中初级(预科和博士后学生,教师)的数量
助理教授)的职业发展。 总而言之,本次会议旨在汇集广泛的
一些研究人员在激肽相关生物学,以促进沟通,合作,和增长的
在年轻的研究人员领域,并继续翻译成治疗一些疾病相关的
NHLBI的使命。
英文摘要
Project Summary
Support is requested for a unique, international, multidisciplinary conference entitled KININ2018CLE
organized by Alvin H. Schmaier, Keith R McCrae, Evi X. Stavrou, Marvin Nieman, Sadashiva S. Karnik, and
Jackson T Wright of Case Western Reserve University (CWRU). This meeting will be held in Cleveland,
Ohio on the CWRU campus from June 17th-20th, 2018. The general topic of this meeting is relevant to the
NHLBI mission since it celebrates the growth of knowledge in several components of the plasma contact,
kallikrein-kinin, and renin angiotensin systems and the translation of that knowledge into therapeutic targets
for several cardiovascular diseases. The contact activation and plasma kallikrein-kinin system have long
been recognized to produce bradykinin and influence blood coagulation, inflammation, fibrinolysis,
complement and the renin-angiotensin systems. These systems consist of biologically active peptides (e.g.
bradykinin, angiotensin II, angiotensin 1-7), their G-protein-coupled receptors (angiotensin receptor 1 and 2,
bradykinin receptor 1 and 2, and Mas), the enzymes that produce these biologic peptides [factor XIIa,
plasma kallikrein, renin, angiotensin converting enzymes, prolycarboxypeptidase, neutral endopeptidase
(neprilysin)], and its natural inhibitor C1 inhibitor. In recent years, the list of disorders that are managed by
targeting members of these systems has extended from hypertension to heart failure, hereditary
angioedema, and arterial thrombosis inhibition without risk of hemorrhage. This meeting is unique because
it will bring together thought leaders in diverse fields to fill gaps in knowledge, to communicate ideas and
build new associations, and to forge new collaborations in academia and industry.
This conference grant (R13) application requests funds for travel awards for trainees (pre-doctoral students,
post-doctoral students, instructors, or assistant professors) for conference registration, travel, and hotel.
These international kinin conferences are held every three years in different locations. The last time it was
held in the United States was in 2002 in Charleston, South Carolina. Since that time, a new generation of
investigators has developed due to several discoveries: 1) all murine models of contact proteins influence
thrombosis risk without bleeding;; 2) multiple novel targets have been used to reduce bradykinin formation in
the management of hereditary angioedema;; 3) previously unappreciated biologic mechanisms for factor XII
activation have been recognized;; and 4) neprilysin combined with angiotensin receptor 1 antagonist have
been recognized as a potent combination of agents to treat heart failure. The research momentum in these
fields has been extraordinary and drives the need for this inter-disciplinary conference.
The goals of KININ2018CLE are several fold: 1) Disseminate the research and clinical progress in kinin
biology since the last meeting in the United States;; 2) Bring together the world’s best investigators in the
field of kinins for sharing research and generation of new ideas to fill gaps in knowledge for future
investigation;; 3) Encourage fertilization of cross-discipline research to stimulate new ideas and unique
research opportunities;; 4) Emphasize those areas where kinin science is now being translated into clinical
use;; and 5) Inspire the next generation of junior investigators in this field to achieve that which their
teachers and mentors were unable to accomplish.
KININ2018CLE objectives are several-fold: 1) Foster communication, sharing of ideas, and future
collaborations among participants;; 2) Clarify unknowns in the fields and infuse new knowledge with re-
interpretations of older information;; 3) Educate a new generation of investigators in these content areas;; 4)
Support career development of new investigators in the field;; 5) Stimulate collaboration between academia
and industry;; 6) Stimulate the pharmaceutical industry interest in new areas where there is potential for
development of therapeutic targets. The success of KININ2018CLE will be measured by several evaluating
tools: 1) We will evaluate each speaker for objectivity, quality, and lack of commercial bias in the
presentation;; 2) An overall meeting evaluation will be performed at conference conclusion;; 3) A meeting
report that will be published in Frontiers in Hematology;; 4) An on-line symposium of each speaker’s
presentation will be published in Frontiers in Hematology within 12 months of the conference;; 5) We will
ascertain the number of abstract speakers who were junior (pre-and post-doctoral students, instructors
assistant professors) in career development. In sum, this conference intends to bring together a wide
number of investigators in kinin-related biology to foster communication, collaboration, and growth of the
field in young investigators and continued translation into therapies for a number of disorders relevant to the
mission of NHLBI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tyrosine Kinases and Thrombosis
-
批准号:10367450
-
项目类别:
-
资助金额:$54.01万
-
财政年份:2022
-
负责人:ALVIN H SCHMAIER
-
依托单位:
Tyrosine Kinases and Thrombosis
-
批准号:10573189
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2022
-
负责人:ALVIN H SCHMAIER
-
依托单位:
Prolylcarboxypeptidase is a Risk Factor for Cardiovascular Disease
-
批准号:8262208
-
项目类别:
-
资助金额:$11.78万
-
财政年份:2012
-
负责人:ALVIN H SCHMAIER
-
依托单位:
Prolylcarboxypeptidase is a Risk Factor for Cardiovascular Disease
-
批准号:8448685
-
项目类别:
-
资助金额:$11.21万
-
财政年份:2012
-
负责人:ALVIN H SCHMAIER
-
依托单位:
CORE--MOUSE COAGULALTION LABORATORY
-
批准号:6504161
-
项目类别:
-
资助金额:$13.59万
-
财政年份:2001
-
负责人:ALVIN H SCHMAIER
-
依托单位:
PLASMA PROTEIN PHENOTYPING OF PROTHROMBOTIC MICE
-
批准号:6527593
-
项目类别:
-
资助金额:$15.09万
-
财政年份:2000
-
负责人:ALVIN H SCHMAIER
-
依托单位:
CORE--MOUSE COAGULALTION LABORATORY
-
批准号:6356277
-
项目类别:
-
资助金额:$21.31万
-
财政年份:2000
-
负责人:ALVIN H SCHMAIER
-
依托单位:
PLASMA PROTEIN PHENOTYPING OF PROTHROMBOTIC MICE
-
批准号:6656245
-
项目类别:
-
资助金额:$15.09万
-
财政年份:2000
-
负责人:ALVIN H SCHMAIER
-
依托单位:
PLASMA PROTEIN PHENOTYPING OF PROTHROMBOTIC MICE
-
批准号:6152956
-
项目类别:
-
资助金额:$15.13万
-
财政年份:2000
-
负责人:ALVIN H SCHMAIER
-
依托单位:
PLASMA PROTEIN PHENOTYPING OF PROTHROMBOTIC MICE
-
批准号:6390790
-
项目类别:
-
资助金额:$15.09万
-
财政年份:2000
-
负责人:ALVIN H SCHMAIER
-
依托单位:
CORE--MOUSE COAGULALTION LABORATORY
-
批准号:6202568
-
项目类别:
-
资助金额:$21.31万
-
财政年份:1999
-
负责人:ALVIN H SCHMAIER
-
依托单位:
Thrombostatin In The Folts Model for Coronary Thrombosis
-
批准号:6338041
-
项目类别:
-
资助金额:$58.56万
-
财政年份:1999
-
负责人:ALVIN H SCHMAIER
-
依托单位:
CORE--MOUSE COAGULALTION LABORATORY
-
批准号:6110821
-
项目类别:
-
资助金额:$21.31万
-
财政年份:1998
-
负责人:ALVIN H SCHMAIER
-
依托单位:
THROMBOSTATIN--A SELECTIVE ANTITHROMBIN
-
批准号:2872942
-
项目类别:
-
资助金额:$32.26万
-
财政年份:1997
-
负责人:ALVIN H SCHMAIER
-
依托单位:
CORE--MOUSE COAGULALTION LABORATORY
-
批准号:6242815
-
项目类别:
-
资助金额:$20.56万
-
财政年份:1997
-
负责人:ALVIN H SCHMAIER
-
依托单位:
THROMBOSTATIN--A SELECTIVE ANTITHROMBIN
-
批准号:2030050
-
项目类别:
-
资助金额:$31.05万
-
财政年份:1997
-
负责人:ALVIN H SCHMAIER
-
依托单位:
THROMBOSTATIN--A SELECTIVE ANTITHROMBIN
-
批准号:2655292
-
项目类别:
-
资助金额:$31.65万
-
财政年份:1997
-
负责人:ALVIN H SCHMAIER
-
依托单位:
REGULATION OF KININ DELIVERY ON HUVEC
-
批准号:6183829
-
项目类别:
-
资助金额:$30.76万
-
财政年份:1996
-
负责人:ALVIN H SCHMAIER
-
依托单位:
Thrombostatin-A Thrombin Receptor Inhibitor
-
批准号:7072202
-
项目类别:
-
资助金额:$60.69万
-
财政年份:1996
-
负责人:ALVIN H SCHMAIER
-
依托单位:
REGULATION OF KININ DELIVERY ON HUVEC
-
批准号:6745141
-
项目类别:
-
资助金额:$32.77万
-
财政年份:1996
-
负责人:ALVIN H SCHMAIER
-
依托单位:
海外基金